Memantine Hydrochloride for Treatment of Cognitive Dysfunction Due to Traumatic Brain Injury

PHASE3CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

January 1, 2024

Primary Completion Date

June 1, 2024

Study Completion Date

August 1, 2024

Conditions
Treatment of Cognitive Deficits After Traumatic Brain Injury
Interventions
DRUG

Memantine Hydrochloride

Memantine was added to each patient's current medication, with the initial dosage of 5 mg/day (once daily). The dosage was then increased to 10 mg/day after a week and maintained till the end of the study. In the case of intolerance to this increase, the dosage was flexibly adjusted according to the condition of the patient.

Trial Locations (1)

71516

Assiut University, Faculty of Medicine, Hospital of Neurology, Psychiatry and Neurosurgery, Asyut

All Listed Sponsors
lead

Assiut University

OTHER

NCT06337994 - Memantine Hydrochloride for Treatment of Cognitive Dysfunction Due to Traumatic Brain Injury | Biotech Hunter | Biotech Hunter